Lexeo Therapeutics’ (LXEO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $23.00 target price on the stock. HC Wainwright also issued estimates for Lexeo Therapeutics’ Q1 2025 earnings at ($0.78) EPS, Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

Several other research analysts also recently commented on LXEO. Chardan Capital restated a “buy” rating and set a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday. Royal Bank of Canada decreased their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday. Finally, Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Monday, March 24th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $22.80.

Lexeo Therapeutics Stock Performance

NASDAQ:LXEO opened at $4.10 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The stock’s fifty day moving average is $4.05 and its 200 day moving average is $6.58. The firm has a market capitalization of $135.57 million, a PE ratio of -1.30 and a beta of 3.85. Lexeo Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. On average, sell-side analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in Lexeo Therapeutics by 86.5% in the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after acquiring an additional 256,635 shares during the period. State Street Corp boosted its holdings in Lexeo Therapeutics by 29.4% during the third quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after buying an additional 57,674 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Lexeo Therapeutics during the third quarter valued at $11,307,000. Barclays PLC increased its holdings in Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after buying an additional 31,057 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares during the period. Hedge funds and other institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.